Skip to main content
David Holliday, MD, Anesthesiology, Washington, DC

DavidJHollidayMD

Anesthesiology Washington, DC

Instructor, Anesthesiology, Howard University College of Medicine

Are you Dr. Holliday?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 80 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    2041 Georgia Ave Nw
    Washington, DC 20060
    Phone+1 202-865-6711
    Fax+1 202-865-6713

Summary

  • Dr. David Holliday, MD is an anesthesiologist in Washington, District of Columbia. He is currently licensed to practice medicine in District of Columbia, Pennsylvania, and Virginia. He is affiliated with Howard University Hospital and is an Instructor at Howard University College of Medicine.

Education & Training

  • George Washington University
    George Washington UniversityResidency, Anesthesiology, 1993 - 1996
  • MedStar Health/Georgetown-Washington Hospital Center
    MedStar Health/Georgetown-Washington Hospital CenterInternship, Internal Medicine, 1992 - 1993
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 1992

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1993 - 2026
  • VA State Medical License
    VA State Medical License 2000 - 2026
  • DC State Medical License
    DC State Medical License 2000 - 2024
  • PA State Medical License
    PA State Medical License 2000 - 2002

Press Mentions

  • Industry Veteran Jim Caggiano Appointed CEO of Evolve Biologics®, as Company Advances Commercialization of Innovative PlasmaCap EBA® Technology to Disrupt $24 Billion Global Plasma-Derived Therapeutics Market
    Industry Veteran Jim Caggiano Appointed CEO of Evolve Biologics®, as Company Advances Commercialization of Innovative PlasmaCap EBA® Technology to Disrupt $24 Billion Global Plasma-Derived Therapeutics MarketJanuary 19th, 2021